scholarly journals Laser photocoagulation control of diabetic macular oedema without fluorescein angiography.

1991 ◽  
Vol 75 (2) ◽  
pp. 97-99 ◽  
Author(s):  
A M Abu el Asrar ◽  
P H Morse
Keyword(s):  
Fluorescein Angiography ◽  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Diabetic Macular Oedema

scholarly journals Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study

2021 ◽  
pp. bjophthalmol-2020-318690
Author(s):  
Kun Liu ◽  
Hanying Wang ◽  
Wei He ◽  
Jian Ye ◽  
Yanping Song ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Sham Group ◽  
Controlled Trial ◽  
Diabetic Macular Oedema ◽  
Intravitreal Injections ◽  
Phase Iii ◽  
Extension Study ◽  
Open Label ◽  
Open Label Extension

BackgroundTo demonstrate the efficacy and safety of intravitreal injections of conbercept versus laser photocoagulation in the treatment of diabetic macular oedema (DME).MethodsA 12-month multicentre, randomised, double-masked, double-sham, parallel controlled, phase III trial (Sailing Study), followed by a 12-month open-label extension study. Patients with centre-involved DME were randomly assigned to receive either laser photocoagulation followed by pro re nata (PRN) sham intravitreal injections (laser/sham) or sham laser photocoagulation followed by PRN 0.5 mg conbercept intravitreal injections (sham/conbercept). Patients who entered the extension study received PRN conbercept treatment. The primary endpoint was the changes in best-corrected visual acuity (BCVA) from baseline.ResultsA total of 248 eyes were included in the full analysis set and 157 eyes continued in the extension study. Significant improvement in mean change in BCVA from baseline to month 12 was observed in the sham/conbercept group (8.2±9.5 letters), whereas no improvement was observed in the laser/sham group (0.3±12.0 letters). Patients in the laser/sham group showed a marked improvement in BCVA after the switch to conbercept in the extension study, and there was no difference in BCVA between the two groups at the end of the extension study.ConclusionThe use of a conbercept PRN intravitreal injection regimen improved the BCVA of patients with DME, and its efficacy was better than that of laser photocoagulations, and the same efficacy was observed when the eyes treated with laser alone were switched to conbercept.Trial registration numberNCT02194634.

scholarly journals Argon laser photocoagulation for diabetic macular oedema

Eye ◽  
2006 ◽  
Vol 20 (12) ◽  
pp. 1471-1472
Author(s):  
N E Sinclair ◽  
A Booth ◽  
A Clover ◽  
R Newsom
Keyword(s):  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Diabetic Macular Oedema ◽  
Argon Laser ◽  
Argon Laser Photocoagulation

scholarly journals Topography of diabetic macular oedema compared with fluorescein angiography

2006 ◽  
Vol 85 (1) ◽  
pp. 32-39 ◽  
Author(s):  
Aljoscha S. Neubauer ◽  
Christos Chryssafis ◽  
Siegfried G. Priglinger ◽  
Christos Haritoglou ◽  
Martin Thiel ◽  
...  
Keyword(s):  
Fluorescein Angiography ◽  
Macular Oedema ◽  
Diabetic Macular Oedema

scholarly journals The predictive value of optical coherence tomography after grid laser photocoagulation for diffuse diabetic macular oedema

2007 ◽  
Vol 86 (3) ◽  
pp. 284-291 ◽  
Author(s):  
Wael Soliman ◽  
Birgit Sander ◽  
Kamell Abd El-Naser Soliman ◽  
Sameer Yehya ◽  
Mohamed Saad Abdel Rahamn ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Macular Oedema ◽  
Predictive Value ◽  
Laser Photocoagulation ◽  
Diabetic Macular Oedema ◽  
Optical Coherence

scholarly journals Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema

2012 ◽  
Vol 96 (5) ◽  
pp. 694-698 ◽  
Author(s):  
Matthew M Wessel ◽  
Nandini Nair ◽  
Grant D Aaker ◽  
Joshua R Ehrlich ◽  
Donald J D'Amico ◽  
...  
Keyword(s):  
Fluorescein Angiography ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Retinal Ischaemia

scholarly journals Subthreshold 577 nm laser photocoagulation vesus conventional 532 nm laser photocoagulation for diabetic macular oedema

2021 ◽  
Vol 3 (3) ◽  
pp. 123-140
Author(s):  
Linda Sui-Lin Ong ◽  
Tajunisah Mohd Iqbal ◽  
Kenneth Choong-Sian Fong
Keyword(s):  
Diode Laser ◽  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Retinal Thickness ◽  
Diabetic Macular Oedema ◽  
Macular Thickness ◽  
Clinically Significant ◽  
Clinically Significant Macular Oedema ◽  
532 Nm

Purpose: To evaluate the visual and anatomic outcomes of the subthreshold micropulse 577 nm yellow diode laser (MYL) and to compare its efficacy with the conventional green 532 nm diode laser (CGL) in Asian eyes with diabetic macular oedema (DME).Study design: Prospective randomized controlled clinical trialMethods: Sixty-seven eyes of 43 patients with clinically significant macular oedema (CSME) were randomized to receive either MYL (n = 37) or CGL (n = 30) at baseline and were followed up for 12 months. Titration in the MYL group was performed with 15% duty cycle, 300 ms duration, and double the threshold power, while the modified Early Treatment of Diabetic Retinopathy Study (mETDRS) protocol was used for the CGL arm with the power titrated to a barely visible burn. Parameters noted included best-corrected visual acuity (BCVA) (logMAR), central subfoveal thickness (CST), macular volume (MV), and average macular thickness (AMT) using optical coherence tomography, and presence of visible laser scars on colour fundus photographs and fundus autofluorescence, at baseline and at 12 months.Results: At 12 months follow-up, BCVA improved by 4.7 and 8.8 letters, respectively, for the MYL and CGL treatment arms (p < 0.05). There was a significant reduction in all retinal thickness parameters (CST, MV, and AMT) when compared to baseline in both laser treatment arms at 12 months. There was no significant difference in either BCVA or retinal thickness parameters between the two treatment arms at 1, 3, 6, 9, or 12-month follow-up. Laser scars were observed in 26.7% of patients in the MYL group compared to 75% of patients in the CGL group (p = 0.029).Conclusions: MYL is an effective, safe, and patient-friendly treatment option for clinically significant macular oedema, with improvement in BCVA, reduction in macular thickness, and less scarring after treatment at 12 months.

Sign in / Sign up

Export Citation Format

Share Document